Allspring Global Investments Holdings LLC Decreases Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Allspring Global Investments Holdings LLC decreased its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 82.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 5,180 shares of the company's stock after selling 24,597 shares during the period. Allspring Global Investments Holdings LLC's holdings in Krystal Biotech were worth $904,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Fifth Third Bancorp increased its holdings in shares of Krystal Biotech by 159.1% during the 1st quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Krystal Biotech during the 4th quarter worth approximately $95,000. GAMMA Investing LLC increased its holdings in shares of Krystal Biotech by 179.3% during the 1st quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after buying an additional 432 shares during the last quarter. Covestor Ltd increased its holdings in shares of Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after buying an additional 642 shares during the last quarter. Finally, US Bancorp DE increased its holdings in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after buying an additional 82 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Trading Down 1.0%

Krystal Biotech stock traded down $1.57 during trading on Friday, hitting $148.17. The company had a trading volume of 267,497 shares, compared to its average volume of 287,362. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $219.34. The company's 50 day simple moving average is $135.82 and its 200-day simple moving average is $156.27. The stock has a market cap of $4.28 billion, a price-to-earnings ratio of 35.62 and a beta of 0.67.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million during the quarter, compared to analysts' expectations of $98.66 million. As a group, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 6,927 shares of the firm's stock in a transaction that occurred on Thursday, July 10th. The shares were sold at an average price of $150.27, for a total value of $1,040,920.29. Following the completion of the transaction, the insider owned 1,525,929 shares of the company's stock, valued at $229,301,350.83. This trade represents a 0.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Over the last three months, insiders have sold 13,927 shares of company stock valued at $2,092,852. Company insiders own 13.70% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KRYS. Citigroup restated a "neutral" rating and set a $176.00 price target (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday. Guggenheim cut their price target on shares of Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, June 24th. Finally, Chardan Capital reiterated a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $213.75.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).